Risk Factors Update Summary

• Increased costs related to public company operations will require hiring additional personnel. This change might result in higher operational expenses.
• The company had no income from continuing operations as of December 31, 2023, and incurred losses of $16,205,252.
• Reduced full-time employees from seven to nine and part-time employees from eight to one. This change may impact operational efficiency and productivity.
• The company expressed substantial doubt about its ability to continue as a going concern, requiring additional funding.
• Emphasized the critical need for substantial additional funding to support ongoing activities, commercialization efforts, and business growth. Failure to secure funding may lead to delays or reductions in development programs.
• Addition of new product candidates may require additional capital, with a working capital of $951,495.
• Compliance with healthcare regulations may become more costly and difficult, impacting business growth.
• The company identified a material weakness in internal financial controls, impacting financial reporting and market value.
• Reprioritized development to focus on commercializing cosmetic products, ceasing clinical studies of product candidates. This change could result in a delay in generating revenue.
• Highlighted the importance of managing inventory efficiently to meet demand, control costs, and avoid inventory-related challenges that could harm long-term growth prospects.
• Management estimates the need to raise additional capital in the next twelve months for development and commercialization.
• The ongoing conflicts globally could disrupt the supply chain, impacting business operations and data security.
• New regulatory requirements for cosmetic products under MoCRA could lead to significant compliance costs.
• Increased the number of skincare products to be launched in 2024 from one to ten. This expansion may require additional resources and marketing efforts.
• Expanded the description of potential risks related to product liability lawsuits, emphasizing the impact on resources, liabilities, and commercialization efforts.
• Changes in the regulatory environment may impact financial arrangements, sales, and marketing programs.
• Added the need to resolve FDA comments on Bone Healing Accelerant program before initiating clinical studies. Failure to resolve may lead to a denial of regulatory approval.
• The company may face challenges in managing growth, with plans to increase personnel and resources.
• The volatility of the stock market may affect the trading price of the company's common stock.
• Failure to comply with regulatory requirements could result in penalties, fines, or operational disruptions.
• Provisions in the company's certificate of incorporation may discourage unsolicited takeover proposals.